Arzerra ofatumumab: Preliminary Phase II data

Preliminary data from an ongoing, open-label, U.S. Phase II trial in 16 evaluable patients with relapsed CLL showed that ofatumumab plus Revlimid lenalidomide produced an ORR of 63%, with 2 complete responses and 8 partial responses, plus 4 cases of stable disease. The most common grade 3/4 adverse events were neutropenia and anemia. The partners plan to enroll 40 patients in the trial. Patients received weekly IV ofatumumab for 4 weeks, then monthly for months 2-6, followed by once every 2 months for months 7-24, plus daily Revlimid starting on day 9. Data will be presented at the American Society of Hematology meeting in Orlando in December. ...